A chatbot might return a single response based on an editorial or opinion piece it "remembers," presenting it as definitive.

The DESTINY-Breast11 trial showed in patients with high-risk HER2-positive early breast cancer that the ADC followed by ...

Medical imaging foundation models are ushering in a new era for precision oncology. By integrating massive multimodal ...

Greco-Hainsworth Centers for Research early phase unit led by Jeffery Russell, MD, PhD, MBA and Joseph Merriman, MD -- As an extension of Tennessee Oncology's Clinical Trials Program, the early phase ...

Jody Agena, PharmD, MBA, director of pharmacy operations, Virginia Cancer Specialists, discusses the various responsibilities of the pharmacist within community oncology settings. The clinical ...

SynOx Therapeutics completed enrollment for the phase 3 TANGENT study of emactuzumab for tenosynovial giant cell tumors, with results expected in 2026. ALX Oncology launched a phase 1 trial of ALX2004 ...

Attendees will understand how new data unveiled at the European Society for Medical Oncology (ESMO) 2025 annual meeting may influence the future of cancer treatment, including shifts in clinical ...

Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and ...

Dr. Matthew Rettig and his research team have been awarded a Clinical Cancer Research Center grant from the U.S. Department of Veterans Affairs to establish a new clinical cancer research center that ...

Joshua K. Sabari, MD, director of High Reliability Organization Initiatives at NYU Langone Health's Perlmutter Cancer Center, ...

BetaGlue® Therapeutics ('BetaGlue” or the 'Company”) a clinical-stage oncology company developing an innovative radiotherapy ...

Teaching Communication Skills and Developing Comfort With Difficult Conversations: A Combined Palliative Care-Oncology Simulation Session for Hematology/Oncology Fellows A systematic, modified Delphi ...